Eduardo Mysler

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 4

Top Topics

Rheumatoid Arthritis

Randomized Controlled Trial

Top Venues

Rheumatology and therapy

Lupus science & medicine

Rheumatology (Oxford, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Grace C Wright, Eduardo Mysler, Kenneth Kwok, Mary Jane Cadatal, Rebecca Germino, Arne Yndestad, Cassandra D Kinch, Alexis Ogdie
Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatology and therapy (2024)
David R W Jayne, Brad H Rovin, Eduardo Mysler, Richard A Furie, Frederic A Houssiau, Teodora Trasieva, Jacob Knagenhjelm, Erik Schwetje, Weifeng Tang, Raj Tummala, Catharina Lindholm
Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus science & medicine 10 (2) (2023)
Eduardo Mysler, Yoshiya Tanaka, Arthur Kavanaugh, Daniel Aletaha, Peter C Taylor, In-Ho Song, Tim Shaw, Yanna Song, Ryan DeMasi, Mira Ali, Roy Fleischmann
Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE. Rheumatology (Oxford, England) (2022)
Eduardo Mysler, Valderilio Feijó Azevedo, Silvio Danese, Daniel Alvarez, Noriko Iikuni, Beverly Ingram, Markus Mueller, Laurent Peyrin Biroulet
Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience? Drugs 81 (16) (2021)